---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-027993"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:11:36.406348+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zevra Therapeutics appoints Neil F. McFarlane as CEO effective Oct 10, 2023

## Summary
- Neil F. McFarlane named President and CEO, succeeding interim CEO Christal Mickle who remains Chief Development Officer.
- McFarlane receives $700k base salary, 60% target bonus, 600k stock options, and 200k RSUs vesting over 4 years.
- Relocation assistance of $350k provided; severance includes 1x salary (1.5x upon change in control).
- Board member Joseph B. Saluri resigned effective immediately after McFarlane's appointment.
- McFarlane brings 25+ years biopharma experience, most recently CEO of Adamas Pharmaceuticals.

## SEC filing metadata
- accession: 0001437749-23-027993
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/0001437749-23-027993-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/zvra20231005_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-027993
- JSON: https://secwatch.observer/filing/0001437749-23-027993.json
- Plain text: https://secwatch.observer/filing/0001437749-23-027993.txt

## Key facts
- Executive change
  Joseph B. Saluri resigned as Board member at ZEVRA THERAPEUTICS, INC..
  - Action: resigned
  - Role: Board member
  source text: Resignation of Joseph B. Saluri from B
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/0001437749-23-027993-index.htm
- Executive change
  Neil F. McFarlane was appointed as President and Chief Executive Officer at ZEVRA THERAPEUTICS, INC..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: appointed Neil F. McFarlane to serve as the Company’s President and Chief Executive Officer, effective October 10, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/0001437749-23-027993-index.htm
- Executive change
  Neil F. McFarlane was appointed as member of the Board at ZEVRA THERAPEUTICS, INC..
  - Action: appointed
  - Role: member of the Board
  source text: Concurrently with his appointment as President and Chief Executive Officer, Mr. McFarlane was appointed to serve as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/0001437749-23-027993-index.htm
- Executive change
  Christal M.M. Mickle changed role as Chief Development Officer at ZEVRA THERAPEUTICS, INC..
  - Action: stepped down as interim President and Chief Executive Officer, continues as Chief Development Officer
  - Role: Chief Development Officer
  source text: succeeding Christal M.M. Mickle., the Company’s former interim President and Chief Executive Officer, in such role. Ms. Mickle will continue serving in her role as Chief Development Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/0001437749-23-027993-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.